Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Profit After Tax (2019 - 2026)

Kymera Therapeutics has reported Profit After Tax over the past 8 years, most recently at -$69.2 million for Q1 2026.

  • Quarterly Profit After Tax fell 5.57% to -$69.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$315.0 million through Mar 2026, down 30.77% year-over-year, with the annual reading at -$311.4 million for FY2025, 39.08% down from the prior year.
  • Profit After Tax was -$69.2 million for Q1 2026 at Kymera Therapeutics, up from -$87.0 million in the prior quarter.
  • Over five years, Profit After Tax peaked at -$14.4 million in Q4 2023 and troughed at -$87.0 million in Q4 2025.
  • The 5-year median for Profit After Tax is -$48.6 million (2024), against an average of -$53.3 million.
  • Year-over-year, Profit After Tax surged 58.79% in 2023 and then crashed 392.43% in 2024.
  • A 5-year view of Profit After Tax shows it stood at -$34.9 million in 2022, then surged by 58.79% to -$14.4 million in 2023, then tumbled by 392.43% to -$70.8 million in 2024, then decreased by 22.94% to -$87.0 million in 2025, then increased by 20.4% to -$69.2 million in 2026.
  • Per Business Quant, the three most recent readings for KYMR's Profit After Tax are -$69.2 million (Q1 2026), -$87.0 million (Q4 2025), and -$82.2 million (Q3 2025).